The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
It’s ironic the ceo has labelled some investors as rainbow chasers in the past when he thinks there is a limitless pot of raises and debt he continues to dip into in order to generate revenue less than the raised debt/equity. This is why the share price has not moved. Instead of having ruthless focus on landing big sales on one-two markets he has tried to fight on all frontiers and rainbow chase any and every opportunity all at once and start to talk about multiple unicorns under this umbrella. Please show us just one unicorn, shareholders will be happy. We can worry about the other later. This inept strategic strategic decisions have exposed the business to high risk and made this in to high risk investment unnecessarily for poor old loyal shareholders who are now at risk at further dilution. Frankly irresponsible. Gloating about growing employee numbers over the last 12 months and this is where we are. Larger overheads and a reasonable uplift from a small revenue figure (bot to mention acquisition). The lack of professionalism in reporting and and consistency between each RNS keeps us all guessing. A quality business has RNS pattern that you could pick up the last 12 months RNS and follow one from another. All we hear is we are busy and we are growing and we need more in the begging bowl. There was a claim 2021 loss was not cash related - so fck knows why another 4m is needed to the ‘9.5m’ revenue from last year. Last chance saloon. There is no real forum where he can be questioned - just a scripted chat with Katie. I think we need to start thinking about launching a shareholder action group soon. Still time to rescue this before he plunders all the cash in the new facility.
This financing deal is so bad. All the little behind the scenes trades and lack of clarity in reporting is now looking to be beyond normal incidental.
Only way I get my money back is if we get bought out. Please let it happen before we get swallowed by the convertibles!
https://www.ft.com/content/b2314ae0-9e17-425d-8e3f-066270388331
https://www.google.com/amp/s/amp.ft.com/content/8ccfa0c6-2cb3-4f9f-a8e3-985d22418b34
Nice rns and interview today.
Not quite clear to me if this was inventory that was not shipped from Q1 sales announcement or new ‘new’ revenue. Can anybody decipher?
Either way, seems like things are so slowly coming together and management becoming increasingly professional.
Thanks - Appreciate the response. COVID hysteria was created and flattened after that disastrous shareholder meeting last October. If £10m is hit this year - it will be ok. But that’s not what the market is indicating.
We haven taken on a lot of costs and without a large contract in the quarter we are not starting to be productive. Investing in innovative solutions is fine but we need one bloody cash cow to stem the tide.
And for those who tell us to ‘move-on’. We can’t at this price!
If anyone could help - be most appreciated.
Where is the value creation in this company (don’t give me stats from the lowest of lows when you can’t give me numbers of actual clients and users of your services)? Where are the directors buying stock? Why is it there is no legitimate forum to get straight answers back to shareholder queries? Who is a rainbow chaser when talking about unicorns? What happens to all the projects/initiatives that slowly evaporate from RNS? Which company CONSISTENTLY miss their own deadlines set in their own RNS? Who measures growth by looking at employee numbers?
There are many more…. But answers to any of these would be helpful.
Let’s hope the rabbits is truly pulled out of the hat in q4.
All i have seen is an imposter waving his/their Pom-poms for msys? Good thing we are 450% up and the share price isn’t 40% down over last year.
Ok… so phase 3 complete for PD. So Presumably still negotiating terms…. May get some sort of an update in q4 i suppose.
Just looking out for potential tangible rns which can stop this slippery slope.
Thanks anyway.
Great. So can you tell me what we can really expect next quarter?
Thanks for the pointers t.rat.
Sorry - Just does not appear to be clear what is going on. I thought phase 3 was for the breath test not the PD. That appears now separate and by ‘expanding the scope’ - China have basically said they need to monitor more pathogens? That right? So we are now dependent on this so-called phase 3 is successful we may get orders from China on the PD? Hope this means additional revenue for the improved capability and no more delays to get a contract in place. Can’t help but feel we should have focused are resources on doing this before we embarked on breath test. But hey - let’s hope we get this all cleared up in final quarter (presentation suggests early prt of the quarter too - so sometime October….). Fingers crossed.
Agree with most of the sentiment and some of the points here, not sure why the SP needs to go any further down though. I don’t care about dilution if it’s above 50p. They just need to nail one of those orders down. Surprised they only started recruiting sales people only recently. Its a tech business and reasonably valued compared to other market players - the skin and water databanks are of considerable value on their own.
MSYS fanfare is gonna take centre stage next week which is gonna upset the dv holders. The focus needs to be on dvrg.
Been away for a bit… so I may have missed stuff - would appreciate any gaps filled in.
When are we expecting an update to this deal? I must have missed it in the RNS? Thought this was gonna be announced back in June and operational in October. Seems to have slipped a quarter - did anyone get a sense of this is rolling in to next year? There were at least ‘2 multi million pound opportunities’ due on top of the 2021 forecast. I don’t believe either have been come in?
Does that mean TP’s 2022 revenues need to be revised?
Seems breath test has also moved into next year - hopefully this will be able to be commercialised! STC all about next year too (at the earliest) since no numbers forthcoming in presentation (no NDA in saying that we have processed x thousand so far and expect to fulfil capacity 6-12m after launch. Bit strange now we talk about 2/3 division when months ago it’s 4 divisions.
I have backed this one big over the last few years and it’s all becoming a bit disappointing. Does not help by comparing apples and pears on the % y-o-y growth - that’s a little insulting. £10m will be hit right?
Parity - is this a non starter?
Msys - is this now going to be be the focus?
Michigan deal going to extend? Thought there was some usa promotion from the water rising institute?
Come on Gerry, the support is there but need to deliver on the big stuff. Time to start knocking the ball out of the park…. (Don’t think we can start calling this ‘overnight’ success as we run into years….)
Agree with the sentiments. Though the question for me is that the market does not value this business like an AI company (and may be for good reason). There are many ‘AI-driven’ businesses which have less revenue, standing and inherent assets than DVRG but are trading at crazy high valuations…. I believe there is a great deal of value in the dvrg, but IMO but not sure we will see it materialise for a while yet.
Just checking - what’s the date today?
I’m sure they just didn’t wanna send anything slapdash out. It is gonna be a structured grammatically correct blockbuster… right? ;)
https://bidstats.uk/tenders/2021/W19/750518492
This contract is either gonna be renewed/rolled forward at end of month or is gonna be amended to include some of the automation to help be more efficient in sampling.
We know what it should be... let’s see if the gov make the right decision shortly.
Sharky
https://www.ft.com/content/6d4cd446-2243-43f4-befd-565b4e880811
Google ai skin diagnostic by photo - not a direct competitor but certainly a complementary (free) service on its way. DVRG more aimed at cosmetic side and providing solutions.
Does anyone know if the skin trust app facilitate taking the picture of the skin? Must be some Additional AI data that can be glued together with the swab that would make it even more powerful.
IMO - STC and labskin are in a very very very strong position regardless. Only a matter of time before the big tech players want to partner up...
Thanks unc.
Difficult to fathom what revenues are going where at the moment. Seems so many arrows fired/horses backed, so many possibilities at this stage - each a business in its own right. I am just trying to figure out what’s likely to commercialise in 2021.
https://youtu.be/Qhs_qw1sZpM
Just updating my financial/valuation models on a few stocks and Was wondering if anybody heard anything about this agreement with parity last year? There were some interesting claims made during this interview - does anyone know if there Any visible commercial deals that were subsequently mentioned that I had missed? Or have they not been announced?
Thanks
Sharky
It must be me - but still quite unclear :what testing is now going on in Aberdeen?What did tests in Liverpool have to do with now only needing sample size of 40 on their own products?I understood the factory testing is for both wastewater and breathalyser - why else would be talking about 1500 individuals at each site? Using both products to model how a cruise liner could adopt. If anyone can shed any light on this it would be appreciated!Sharky